Eli Lilly and Company (NYSE:LLY) Shares Sold by Souders Financial Advisors

Souders Financial Advisors trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 3.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,157 shares of the company’s stock after selling 108 shares during the quarter. Souders Financial Advisors’ holdings in Eli Lilly and Company were worth $1,841,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Simon Quick Advisors LLC boosted its position in Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $363,000. Liontrust Investment Partners LLP acquired a new position in shares of Eli Lilly and Company in the 3rd quarter worth approximately $8,326,000. WASHINGTON TRUST Co lifted its holdings in Eli Lilly and Company by 16.5% during the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after buying an additional 2,671 shares in the last quarter. Finally, Armstrong Fleming & Moore Inc bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $357,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 2.1 %

LLY traded up $16.13 during midday trading on Friday, hitting $784.21. The company had a trading volume of 2,102,692 shares, compared to its average volume of 2,595,050. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock’s 50 day moving average price is $750.88 and its 200 day moving average price is $645.61. The company has a market capitalization of $745.12 billion, a price-to-earnings ratio of 135.26, a PEG ratio of 1.69 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $363.04 and a 52 week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.09 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research reports. Wells Fargo & Company increased their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Truist Financial restated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday. Citigroup increased their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $700.00.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 180,667 shares of company stock valued at $116,186,189 over the last three months. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.